Literature Review

Closure of High-Risk PFOs Reduces Risk of Recurrent Stroke


 

Because the DEFENSE-PFO study was terminated early for patient safety, it was underpowered to provide a hazard ratio for its primary end point. In addition, selection bias may have affected the study, since it was conducted at a small number of centers.

—Erik Greb

Suggested Reading

Lee PH, Song J-K, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSE-PFO trial. J Am Coll Cardiol. 2018 Mar 12 [Epub ahead of print].

Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011-1021.

Pages

Recommended Reading

AHA and ASA Publish New Ischemic Stroke Guidelines
MDedge Neurology
Mexican Americans With Midlife Stroke May Have Worse Outcomes Than Non-Hispanic Whites
MDedge Neurology
What Is the Impact of Poststroke Cognitive Impairment in Patients With Mild Stroke?
MDedge Neurology
Overweight and obese individuals face greater cardiovascular morbidity
MDedge Neurology
Rivaroxaban Plus Aspirin Nearly Halves Ischemic Stroke Risk
MDedge Neurology
Conference News Roundup—American Association for the Advancement of Science
MDedge Neurology
Migraine May Be an Important Risk Factor for Cardiovascular Diseases
MDedge Neurology
Trial shows ‘signals’ in favor of general anesthesia during EVT for stroke
MDedge Neurology
Defensive medicine’s stranglehold on the realities of practice
MDedge Neurology
Transporting stroke patients directly to thrombectomy boosts outcomes
MDedge Neurology

Related Articles